DexCom (NASDAQ:DXCM) had its target price increased by Oppenheimer from $167.00 to $180.00 in a research note published on Thursday, The Fly reports.
Several other brokerages have also weighed in on DXCM. UBS Group increased their target price on DexCom from $140.00 to $160.00 and gave the stock a neutral rating in a research report on Thursday. BidaskClub raised DexCom from a hold rating to a buy rating in a research report on Tuesday, July 23rd. TheStreet raised DexCom from a d+ rating to a c rating in a research report on Friday, June 28th. BMO Capital Markets increased their target price on DexCom from $167.00 to $172.00 and gave the stock an outperform rating in a research report on Thursday, May 2nd. Finally, Zacks Investment Research raised DexCom from a hold rating to a buy rating and set a $138.00 target price on the stock in a research report on Monday, May 6th. Five investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. The stock presently has an average rating of Buy and an average price target of $163.71.
DXCM traded down $4.11 during trading hours on Thursday, hitting $144.21. 1,234,833 shares of the stock were exchanged, compared to its average volume of 853,906. The stock has a 50-day simple moving average of $149.93. DexCom has a 12 month low of $105.05 and a 12 month high of $161.30. The firm has a market capitalization of $13.52 billion, a PE ratio of 480.70 and a beta of 0.80. The company has a debt-to-equity ratio of 1.56, a quick ratio of 6.75 and a current ratio of 6.05.
DexCom (NASDAQ:DXCM) last issued its earnings results on Wednesday, July 31st. The medical device company reported $0.08 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.01 by $0.07. DexCom had a positive return on equity of 10.41% and a negative net margin of 13.96%. The firm had revenue of $336.40 million for the quarter, compared to analyst estimates of $304.40 million. During the same period last year, the company earned ($0.10) earnings per share. The firm’s revenue for the quarter was up 38.7% on a year-over-year basis. As a group, equities research analysts anticipate that DexCom will post 0.94 earnings per share for the current fiscal year.
In other news, SVP Patrick Michael Murphy sold 400 shares of the firm’s stock in a transaction on Friday, May 10th. The stock was sold at an average price of $116.92, for a total transaction of $46,768.00. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Richard Doubleday sold 2,016 shares of the firm’s stock in a transaction on Tuesday, July 23rd. The shares were sold at an average price of $153.56, for a total value of $309,576.96. Following the transaction, the executive vice president now directly owns 72,570 shares in the company, valued at $11,143,849.20. The disclosure for this sale can be found here. Insiders have sold 63,065 shares of company stock worth $8,207,313 over the last three months. Corporate insiders own 1.80% of the company’s stock.
Several institutional investors and hedge funds have recently modified their holdings of DXCM. Bingham Osborn & Scarborough LLC boosted its stake in DexCom by 12.0% during the second quarter. Bingham Osborn & Scarborough LLC now owns 20,956 shares of the medical device company’s stock valued at $3,140,000 after buying an additional 2,241 shares in the last quarter. Comerica Bank boosted its stake in DexCom by 3.1% during the second quarter. Comerica Bank now owns 19,205 shares of the medical device company’s stock valued at $2,834,000 after buying an additional 569 shares in the last quarter. C WorldWide Group Holding A S boosted its position in shares of DexCom by 352.5% in the 2nd quarter. C WorldWide Group Holding A S now owns 121,949 shares of the medical device company’s stock valued at $18,273,000 after purchasing an additional 95,000 shares during the period. Envestnet Asset Management Inc. boosted its position in shares of DexCom by 33.6% in the 2nd quarter. Envestnet Asset Management Inc. now owns 46,285 shares of the medical device company’s stock valued at $6,935,000 after purchasing an additional 11,637 shares during the period. Finally, Candriam Luxembourg S.C.A. boosted its position in shares of DexCom by 7.7% in the 2nd quarter. Candriam Luxembourg S.C.A. now owns 6,207 shares of the medical device company’s stock valued at $926,000 after purchasing an additional 444 shares during the period. 96.27% of the stock is currently owned by institutional investors.
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Featured Story: What are the benefits of momentum investing?
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.